High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma

Philip Weir; Lenke Besse; Andrej Besse; Cristian Driessen; Mary Frances McMullin; Lisa Crawford; David Donaldson

doi:10.1016/S2152-2650(22)00447-5

High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma

Philip Weir^*, Lenke Besse, Andrej Besse, Cristian Driessen, Mary Frances McMullin, Lisa Crawford, David Donaldson

^*Corresponding author for this work

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Article number	P-117
Pages (from-to)	S99-S100
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	22
Issue number	Supplement
DOIs	https://doi.org/10.1016/S2152-2650(22)00447-5
Publication status	Published - 25 Aug 2022

Access to Document

10.1016/S2152-2650(22)00447-5Licence: Unspecified

Cite this

Weir, P., Besse, L., Besse, A., Driessen, C., McMullin, M. F., Crawford, L., & Donaldson, D. (2022). High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 22(Supplement), S99-S100. Article P-117. https://doi.org/10.1016/S2152-2650(22)00447-5

@article{b280bd809485427ea954be1aa761f091,

title = "High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma",

author = "Philip Weir and Lenke Besse and Andrej Besse and Cristian Driessen and McMullin, {Mary Frances} and Lisa Crawford and David Donaldson",

year = "2022",

month = aug,

day = "25",

doi = "10.1016/S2152-2650(22)00447-5",

language = "English",

volume = "22",

pages = "S99--S100",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Elsevier Inc.",

number = "Supplement",

}

Weir, P, Besse, L, Besse, A, Driessen, C, McMullin, MF , Crawford, L & Donaldson, D 2022, 'High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma', Clinical Lymphoma, Myeloma and Leukemia, vol. 22, no. Supplement, P-117, pp. S99-S100. https://doi.org/10.1016/S2152-2650(22)00447-5

High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma. / Weir, Philip; Besse, Lenke; Besse, Andrej et al.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, No. Supplement, P-117, 25.08.2022, p. S99-S100.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - High throughput metabolism related drug screening identifies hypoxia inducible factor-1 alpha as a promising therapeutic target in proteasome inhibitor resistant multiple myeloma

AU - Weir, Philip

AU - Besse, Lenke

AU - Besse, Andrej

AU - Driessen, Cristian

AU - McMullin, Mary Frances

AU - Crawford, Lisa

AU - Donaldson, David

PY - 2022/8/25

Y1 - 2022/8/25

U2 - 10.1016/S2152-2650(22)00447-5

DO - 10.1016/S2152-2650(22)00447-5

M3 - Meeting abstract

SN - 2152-2650

VL - 22

SP - S99-S100

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - Supplement

M1 - P-117

ER -